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PURPOSE. To provide structural and functional evidence of inner retinal loss in diabetes
prior to vascular changes and interpret the structure-function relationship in the context
of an established neural model.
METHODS. Data from one eye of 505 participants (134 with diabetes and no clinically
evident vascular alterations of the retina) were included in this analysis. The data were
collected as part of a large population-based study. Functional tests included best-
corrected visual acuity, Pelli-Robson contrast sensitivity, mesopic microperimetry, and
frequency doubling technology perimetry (FDT). Macular optical coherence tomogra-
phy volume scans were collected for all participants. To interpret the structure-function
relationship in the context of a neural model, ganglion cell layer (GCL) thickness was
converted to local ganglion cell (GC) counts.
RESULTS. The GCL and inner plexiform layer were significantly thinner in participants
with diabetes (P < 0.05), with no significant differences in the macular retinal nerve fiber
layer or the outer retina. All functional tests except microperimetry showed a significant
loss in diabetic patients (P < 0.05). Both FDT and microperimetry showed a significant
relationship with the GC count (P < 0.05), consistent with predictions from a neural
model for partial summation conditions. However, the FDT captured additional significant
damage (P = 0.03) unexplained by the structural loss.
CONCLUSIONS. Functional and structural measurements support early neuronal loss in
diabetes. The structure-function relationship follows the predictions from an established
neural model. Functional tests could be improved to operate in total summation condi-
tions in the macula, becoming more sensitive to early loss.
Keywords: diabetes, retinal ganglion cells, microperimetry, OCT, spatial summation
Diabetic retinopathy (DR) is the leading cause of blind-ness worldwide in working-age adults.1–3 The role of
vascular damage and new vessel proliferation is widely
recognized and is ultimately responsible for the loss of
sight.1,3 However, recent evidence suggests that direct retinal
neuronal damage in diabetic patients might precede evident
changes to the retinal blood vessels4 and be a risk factor for
progression to DR.5 The damage mainly manifests as reti-
nal ganglion cell (RGC) loss through apoptosis, resembling
other neurodegenerative diseases.6–8
Both functional and structural evidence has been
provided to support RGC loss in diabetic patients. Several
imaging studies, earlier with scanning laser polarimetry9–11
and more recently with spectral domain optical coherence
tomography (SD-OCT), observed thinning of the ganglion
cell layer (GCL), retinal nerve fiber layer (RNFL), and inner
plexiform layer (IPL) in patients with minimal or no vascu-
lar diabetic retinopathy.4,12–17 A wide array of tests have
also been employed to detect the functional implications
of such structural changes. Besides visual acuity, reported
in almost all studies, functional tests have included Pelli-
Robson contrast sensitivity,18–20 microperimetry,20–24 Rarebit
perimetry,18,25,26 frequency doubling technology perimetry
(FDT),18,19,27–29 standard automated perimetry (SAP),18,28–31
and quick contrast sensitivity function (qCSF).18 All these
functional assessments have been able to show, to a differ-
ent extent, some degree of functional impairment in patients
with diabetes mellitus (DM) with no or minimal DR when
compared to people without DM. Microperimetry is partic-
ularly appealing for its high spatial accuracy and has been
used for topographical structure-function mapping of early
diabetic damage.20,22 FDT perimetry has also shown promis-
ing results in this context and is particularly valuable for
its sensitivity to inner retina damage.19,32 Jackson et al.,19
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Parravano et al.,29 Joltikov et al.,18 and Bao et al.27 all
reported reduced sensitivity to FDT stimuli in patients with
early or no DR.
Many of these effects in visual function are, however,
subtle and difficult to identify. Although structural analy-
ses on large databases of OCT scans exist,16,17 functional
tests have been performed on much smaller cohorts, espe-
cially when considering diabetic people with no vascular
damage. The only large-scale functional testing results in
people with DM and no DR come from a screening survey
performed in the United States27 with a suprathreshold FDT
test. The study confirmed the usefulness of FDT as an indi-
cator of early inner retinal damage in diabetes. However,
the absence of measured sensitivity thresholds and struc-
tural data prevented a comprehensive quantification of the
structural and functional damage and their relationship.
In this work, we use prospectively collected structural
(SD-OCT) and functional data from a large cohort of healthy
people and diabetic patients with no DR to characterize
early neuronal damage in diabetes. The data are part of a
population-based collection, the Northern Ireland Sensory
Ageing (NISA) study (https://clinicaltrials.gov/ct2/show/
NCT02788695), conducted at Queen’s University Belfast
(QUB). The functional data include best-corrected visual
acuity (BCVA), Pelli-Robson log10 contrast sensitivity (PR-
logCS), microperimetry, and FDT threshold perimetry. We
use these data to test the hypothesis that structural and func-
tional damage of the inner retina is present in DM prior to
clinically evident vascular changes.
METHODS
Data Collection
The NISA study (https://clinicaltrials.gov/ct2/show/
NCT02788695) is a follow-up to the NICOLA (Northern
Ireland Cohort for the Longitudinal Study of Ageing) study
(https://www.qub.ac.uk/sites/NICOLA/), a prospective
population-based study of early imaging and functional
biomarkers of DR and age-related macular degeneration
(AMD). The selection steps are illustrated in a flowchart
in the Appendix. The NICOLA study involved a computer-
assisted home interview followed by a health assessment
at the Northern Ireland Clinical Research Facility (NICRF),
including an evaluation of eye health. People from the
NICOLA cohort with at least one of the following charac-
teristics were invited for the NISA follow-up data collection:
(1) no retinal diseases, (2) self-reported diagnosis of DM
either during the home interview or the health assessment,
and (3) early or intermediate AMD. The sample of diabetic
people (type I or type II) was then extended with patients
recruited directly from the Belfast Trust Diabetic Retinopa-
thy Hospital Clinics at QUB. Participants underwent BCVA
test with an Early Treatment Diabetic Retinopathy Study
(ETDRS) chart, PR-logCS test with a Pelli-Robson chart,
microperimetry and FDT perimetry (described in detail in
the following paragraphs), an SD-OCT scan (described in
detail in the next paragraph), fundus color picture (CX-1
Digital Fundus Camera; Canon U.S.A., Inc, Tokyo, Japan),
color ultra-wide-field imaging (UWFI) images centered
on the fovea (Optomap Panoramic 200Tx scanning laser
ophthalmoscope; Optos PLC, Dunfermline, Scotland, UK),
and a measurement of axial length (AL; Lenstar LS 900
Biometer, Haag-Streit AG, Köniz, Switzerland). Lens opacity
in phakic eyes was graded with a Pentacam Scheimpflug
System (Oculus, Wetzlar, Germany) using the Pentacam
Nucleus Staging (PNS) classification.33 All imaging was
performed after pharmacologic dilation with tropicamide
1%. For all participants, the eye with better BCVA was
selected for the study, choosing at random if they were both
eligible.
Fundus color pictures for all participants were classified
by two graders (authors RD and UC) to identify signs of
AMD (Beckman classification)34 and DR. Disc and macula
color images and UWFI were assessed for characteristic DR
features in the central and peripheral retina and then staged
using the national screening for DR system for England
and Wales into four levels: none (R0), background (R1),
preproliferative (R2), and proliferative (R3). Participants not
recruited from the DR clinic were identified as diabetic if
they self-reported a diagnosis of DM. The duration of the
disease was also recorded when provided. All participants
over 50 years of age and all diabetic patients were also
invited to have a blood sample taken to measure the concen-
tration of plasma glycated hemoglobin (HbA1C). Partici-
pants with no record of diabetes were classified as diabetic
if the HbA1C was ≥6.5%. Refusal to have the blood sample
taken did not prevent inclusion.
Only healthy participants (starting n = 406) or diabetic
patients classified as R0 (starting n = 159) were consid-
ered for this analysis. Eyes with intermediate or advanced
AMD were also excluded (n = 17). People with signs of
early AMD were included in the analysis to avoid overse-
lection of participants, especially for the no-DM cohort. Of
the remaining 548, we only selected people for whom either
microperimetry or FDT was available (n = 545). Hence, the
following selection steps were applied to a starting sample
of 395 healthy participants and 150 diabetic patients.
SD-OCT Scans
Structural data were collected using a Spectralis SD-OCT
(Heidelberg Engineering, Heidelberg, Germany). A macu-
lar volume scan was acquired for each study eye. The
volume was composed of 61 horizontal B-scans (ART 9)
covering a rectangular patch 30 × 25 degrees tilted by 7
degrees (counterclockwise for right eyes, clockwise for left
eyes) to match the average inclination of the fovea-disc
axis (Fig. 1). The scans were tracked on the retina using
a scanning laser ophthalmoscope (SLO) that continuously
captured an infrared fundus picture to compensate for eye
movements. A circumpapillary RNFL (cp-RNFL) scan was
also collected for the study eye. All images were evalu-
ated by two graders (authors RD and UC) to identify poor-
quality scans and manually correct the segmentations where
necessary. Poor quality was defined as the inability to accu-
rately identify all retinal layers either because of low signal
strength or because of partially or totally out-of-frame scans.
An ophthalmologist (GM) visually inspected all scans from
eyes that matched the inclusion criteria (described above)
to identify people with vitreo-retinal alterations (such as
vitreo-retinal tractions or epiretinal membranes), focal loss
of the inner retina on macular scans or of the RNFL on the
cp-RNFL scans (either from vascular occlusions or possible
glaucoma), and diffused advanced cp-RNFL thinning and/or
optic nerve head (ONH) cupping likely attributable to glau-
comatous damage. Standard white-on-white perimetry and a
measurement of the intraocular pressure were not obtained
for this data collection. Hence, a careful selection based on
structural criteria was necessary. A total of 14 eyes were
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FIGURE 1. Schematic of the stimulus displacement applied for the topographic structure-function analysis, overlaid to the GCL thickness
map from the Spectralis SD-OCT. Areas enclosed within the black lines were used for calculations. Microperimetric stimuli were mapped by
aligning the fundus images from the MAIA and the Spectralis. FDT stimuli were centered on the fovea.
excluded due to poor quality of the scans, 10 due to the
presence of vitreo-retinal diseases, and 16 due to focal inner
retinal loss or possible glaucoma. The same criteria were
applied to cp-RNFL scans for participants whose macular
scan was included, leading to the exclusion of 119 of 505
scans (14 from diabetic patients), all because of poor qual-
ity. The absence of a viable cp-RNFL did not prevent inclu-
sion in the analysis. Hence, selection was only based on the
macular scans. For the final selection of scans, the median
(interquartile range) quality index was 30.7 (28.9, 32.5) dB
for the macular scans and 29.3 (23, 34.7) dB for the cp-RNFL
scans.
Microperimetry. Microperimetric data were collected
using a MAcular Integrity Assessment device (MAIA; Center-
Vue, Padua, Italy). The MAIA performs continuous infrared
imaging of the retina to track and compensate for eye move-
ments occurring during the test.35–37 The test was performed
in mesopic conditions (1.27 cd/m2 background illumination)
with an achromatic stimulus (0.43 degrees diameter) using
a 4-2 staircase strategy. At the beginning of the test, a 10-
second fixation trial was used to locate the preferred retinal
locus (PRL) of fixation, used as the center of the perimetric
grid. Notice that this might not coincide with the anatomi-
cal fovea. All tests were preceded by a training phase with
the “fast” protocol to minimize learning effect. The grid was
composed of 44 locations distributed on five concentric rings
at 1, 2.3, 4, 6, and 10 degrees of eccentricity from the PRL. No
exclusion was performed based on fixation metrics or blind
spot responses since, given the use of fundus tracking, these
metrics are unlikely to be related to the reliability of the test.
Furthermore, in a previous analysis, we have shown both
these metrics to be poor predictors of test-retest variability
in microperimetry.38
FDT Perimetry. FDT data were collected with a Matrix
device (Zeiss Meditec, Dublin, CA, USA). The test was
performed with the 24-2 threshold program. The stimuli
were 5 degree squares with a vertical sine wave grating (0.5
cycles/degree) counterphase flickered at 18 Hz. The thresh-
old was measured using a Zippy Estimation through Sequen-
tial Testing (ZEST)39 strategy. Only one eye per participant
was tested (the same as microperimetry when both were
performed). In contrast to microperimetry and standard SAP,
Matrix FDT uses Michaelson’s definition of contrast instead
of Weber’s.40 In the context of sinusoidal grating stimuli,
they are, however, equivalent.41 Importantly, the Matrix FDT
defines the sensitivity scale so that change of one log10 unit
of contrast corresponds to 20 dB instead of 10 dB, as in
microperimetry and SAP.40 Two tests were excluded due to
high false-positive errors (>33%).
Data Analysis
Structural Metrics. All OCT data were exported as
RAW files (.vol) using the Heidelberg Eye Explorer. The files
were then read in MATLAB (MathWorks, Natick, MA, USA)
using a custom-made code. The segmentations were used
to generate thickness maps for the whole retina, the RNFL,
the GCL, the IPL, and the outer retina (from the outer limit
of the IPL to the Bruch’s membrane). The maps were inter-
polated and smoothed to match the size of the reference
infrared fundus image (768 × 768 pixels, 30 × 30-degree
field of view), padding with zeros where the OCT data were
missing (i.e., outside the scanning pattern). The interpola-
tion was performed using a thin plate spline (tpaps function
in MATLAB) with anisotropic smoothing parameters, so that
smoothing was stronger across B-scans than within a B-scan.
The fovea was automatically identified through template
matching. Correct detection was confirmed through visual
inspection.
Topographic average thickness values for all layers were
measured using a standard ETDRS grid, with three concen-
tric rings of 1 mm, 3 mm, and 6 mm external diameter.
The two outermost rings were divided into four sectors
(superior, inferior, nasal, and temporal). The size of the
grid was corrected for AL using our implementation of a
schematic eye42 proposed by Drasdo and Fowler.43 The
statistical analysis was performed in R (R Foundation for
Statistical Computing, Vienna, Austria) using a linear mixed-
effect model with a random intercept to account for multi-
ple measurements (different sectors) from the same eye.
The response variable was the measured thickness, and
the model included a categorical fixed effect for the group
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(either healthy or diabetic), a categorical fixed effect for
the sector, the interaction between the two fixed effects,
and age (years) as a continuous predictor. The P values
were corrected for multiple comparisons (n = 9 tests) with
the Bonferroni-Holm method.44 Finally, global differences
between the two groups across all sectors were tested for
each layer by setting the sector as a crossed random effect.
Global age-corrected differences are reported as estimate
(95% confidence interval [CI]). The α level was 0.05 for all
analyses.
The cp-RNFL scans were corrected for ocular magnifica-
tion using the formula provided by Kang et al.45 However,
such a compensation and other similar methods proposed
introduce a positive correlation with AL, which then needs
to be accounted for in the analysis.45,46 Therefore, when
analyzing the cp-RNFL scans, we included AL as a covari-
ate, together with age.
Functional Metrics. Microperimetric and FDT data
were exported as XML files and read in MATLAB. The mean
sensitivity (MS) for MAIA tests was calculated excluding
the foveal location, which was not used for the structure-
function analysis (see later). The Matrix FDT provides a
calculation of the global mean deviation (MD), pattern stan-
dard deviation (PSD), and values for the pointwise sensi-
tivity, total deviation (TD), and pattern deviation (PD). We
additionally calculated the global MS as the average of the
52 locations within the 24-2 grid, excluding the two blind
spot locations. Since our main analysis focused on the macu-
lar region, we only used pointwise data for the 12 central
locations (within 10 degrees from fixation). Global indices
for the macula were also calculated as the average of the
12 corresponding central TD values (central mean devia-
tion, cMD) and the central sensitivity values (central mean
sensitivity, cMS). All statistical comparisons, including for
BCVA and PR-logCS, were performed with simple multivari-
ate linear models with age as a covariate, except for the MD
and the cMD, which already account for normal aging. BCVA
was converted from letter counts to log10 minimum angle of
resolution (logMAR) for analysis.
Structure-Function Relationship. For our main
structure-function analysis, we focused on the GCL, assumed
to be mostly composed of the bodies of the RGC neurons.
The GCL thickness maps were transformed into estimates
of local RGC density using the method proposed by Raza
and Hood47 and based on the histology maps by Curcio and
Allen.48 The maps were corrected for axial length assuming
a global expansion model, as previously described.42 These
density maps can then be used to derive customized local or
global RGC counts.
Global Structure-Function Relationship. The global
structure-function relationship was studied using the MS for
the MAIA and the cMD and cMS for the FDT. The functional
metric was used as the response variable. The structural
parameter was the total number of RGCs within 12 degrees
from the fovea, covering the area tested by both the 12
central FDT and the MAIA grid after accounting for RGC
displacements (see next paragraph). The MS for the MAIA
and FDT tests was analyzed using a multivariate model that
included age as a covariate. The RGC counts were log10
transformed prior to analysis to match the scale of peri-
metric data. This is also a widely applied method to relate
RGC counts to perimetric sensitivities42,49–51 (see also the
Appendix). A secondary analysis of the correlation between
global FDT MS with the average cp-RNFL (corrected for
ocular magnification45) thickness was also performed, with
age and AL as covariates.
Topographic Structure-Function Relationship. We used
pointwise data to explore the local structure-function rela-
tionship at different eccentricities. The structural metric was
the local RGC count corresponding to each location. We
accounted for RGC displacement in the macular region using
our generalized implementation42 of the model proposed by
Drasdo et al.52 Instead of simply displacing the center of
the tested locations, we displaced the whole perimeter of
the stimuli, since we have previously proven this to be the
correct method to obtain accurate structurally derived RGC
counts42 (Fig. 1).
Since the same RGC count could produce a different
psychophysical sensation (i.e., sensitivity) at different eccen-
tricities, especially in the perifoveal region, our structure-
function models used a categorical fixed effect to account
for eccentricity. An interaction term with the log10(RGC
counts) also allowed for a different slope for each eccen-
tricity. Finally, an interaction term between the eccentricity
fixed effect and the group fixed effect (healthy or diabetic)
allowed for formal testing of statistically significant differ-
ences in slopes between the two groups, which would indi-
cate different change in sensitivities with the same change
in RGC count. A more detailed explanation of the model and
its interpretation is given in the Appendix. For FDT data, the
categorical fixed effect identified each one of the 12 central
locations as a separate level. For the MAIA, locations were
instead grouped by their eccentricity from the PRL. Prior to
analysis, the fundus image from the MAIA was matched with
the SLO fundus picture from the Spectralis SD-OCT using
an affine or projective transformation, so that the tested
locations could be accurately reported onto the structural
maps. The alignment was performed in MATLAB and visu-
ally inspected (GM) to ensure it was correct. When incorrect,
the alignment was repeated by placing manual landmarks on
the two images. A satisfactory alignment could be obtained
for all the included OCT/MAIA pairs. Manual intervention
was required for 327 of 486 alignments.
RESULTS
Sample Description
Descriptive statistics of the selected sample are reported
in the Table. Some participants were unable to complete
the entire imaging and functional testing protocol due to
fatigue or time constraints. Only people with a viable macu-
lar scan and either the FDT or microperimetric test available
were included. The Table also reports the number of partic-
ipants for whom each variable/test was available. Eleven
participants (10 healthy) had an intraocular lens implant.
Three healthy participants and six diabetic patients had a
PNS >1. The AL was measured for 495 participants and
was derived through linear regression from the spherical
equivalent for the remaining 10 participants (none of whom
were pseudophakic). Despite a small difference in the aver-
age age composition, the two groups largely overlapped,
and the main age clusters for diabetic patients were well
represented in the healthy cohort. Microperimetry and FDT
were available together for 412 participants (117 with DM).
Thirteen participants were diagnosed with diabetes during
the study because of their HbA1C value. Nineteen patients
in this cohort had type I diabetes. Twenty-three partici-
pants had sings of early AMD, all in the no-DM cohort. The
cp-RNFL scan was available for 386 people (118 with
diabetes). All of these had performed the FDT test.
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TABLE. Descriptive Statistics of the Analyzed Sample
Characteristic No DM DM No. (No DM/DM)
Age, y 61 (51, 66) 67 (58.25, 72) 371/134
Sex, M:F, No. 208:163 88:46 371/134
Duration of diabetes, y — 0.2 (0.1, 0.43) —/133
HbA1C, % 5.57 (5.31, 5.89) 7.21 (6.52, 8.28) 271/118
Spherical equivalent, diopters 0.38 (−0.75, 1.38) 0.38 (−0.62, 1.47) 369/134
Axial length, mm 23.65 (22.96, 24.4) 23.49 (22.81, 24.15) 371/134
BCVA (logMAR) −0.08 (−0.14, 0) −0.02 (−0.08, 0.04) 371/133
PR-logCS (log) 1.65 (1.65, 1.65) 1.5 (1.5, 1.65) 370/133
MAIA (MS, dB) 27.23 (26.09, 28.11) 26.56 (25.42, 27.88) 360/126
FDT (global MD, dB) −1.53 (−3.45, 0.17) −2.32 (−4.43, −0.05) 306/125
Age cluster, y <30 30–39 40–49 50–59 60–69 70–79 >80
Healthy, No. (%) 36 (10) 23 (6) 26 (7) 84 (23) 155 (42) 45 (12) 2 (1)
Diabetes, No. (%) 3 (2) 8 (6) 3 (2) 23 (17) 47 (35) 45 (34) 5 (4)
Continuous variables are reported as median (interquartile range).
FIGURE 2. Boxplots of the average thickness values recorded for each ETDRS sector. The boxes enclose the interquartile range, and the
whiskers extend to the 95% quantiles. P values were corrected for nine tests with the Bonferroni-Holm method for age-corrected comparisons.
*P < 0.05. **P < 0.01.
Structural Metrics
Global average thickness across all sectors was significantly
reduced in patients with DM for the whole retina (differ-
ence estimate [95% CIs]: –3.47 [–6.09 to –0.84] μm, P =
0.010), the GCL (–1.04 [–1.74 to –0.35] μm, P = 0.003), and
the IPL (–1.89 [–3.09 to –0.69] μm, P = 0.002). No signifi-
cant difference was found for the RNFL (0.11 [–0.52 to 0.74]
μm, P = 0.730). The outer retina was generally thinner in
the DM group, but this difference did not reach statistical
significance (–1.65 [–3.37 to 0.07] μm, P = 0.061). The total
macular log10(RGC count) was also significantly smaller in
diabetic patients (0.011 [0.004 to 0.019] log10-unit reduction,
P = 0.036). All comparisons were age-corrected by includ-
ing age as a covariate, which was significantly negatively
correlated with the thickness of all retinal layers (P < 0.001).
Sector differences are reported in Figure 2. Significant differ-
ences (Bonferroni-Holm corrected P < 0.05) were found for
the GCL and IPL in all 3-mm ring sectors and for the 6-
mm nasal sector for all layers except the RNFL. In the DM
cohort, the thickness of none of the layers was significantly
correlated with either the HbA1C or the duration of diabetes.
The average cp-RNFL, compensated for ocular magnifica-
tion45 and corrected by age and axial length, was also signif-
icantly thinner in the DM cohort (–2.27 [–0.22 to –4.64] μm,
P = 0.032).
Functional Metrics
Diabetic people had a significantly lower PR-logCS (age-
corrected estimated difference: –0.09 [–0.11 to –0.06], P <
0.001) and the BCVA (0.05 [0.03 to 0.07] logMAR, P < 0.001).
There was no significant difference in microperimetric MS in
the age-corrected comparison (–0.21 [–0.52 to 0.1] dB, P =
0.188). There was, however, a statistically significant differ-
ence in FDT cMD (–0.94 [–1.65 to –0.23] dB, P = 0.010) and
FDT MD (–0.83 [–1.53 to –0.13], P = 0.021). A significant
difference was also found for the age-corrected FDT cMS (–
1.02 [–1.75 to –0.28], P = 0.007). In the DM cohort, none
of the functional metrics were significantly correlated with
either the HbA1C or the duration of diabetes.
Structure-Function Relationship.
Global Structure-Function Relationship. A significant
correlation with the total macular log10(RGC count) was
found for the microperimetric MS (P = 0.0212) and for both
central FDT metrics (cMD, P = 0.002; MS, P < 0.001). There
was no significant difference in slopes between diabetic
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FIGURE 3. Scatterplot and regression lines for the global structure-function relationship. The regression lines have the same slope for both
healthy and diabetic people. The total RGC count was calculated within the central 12 degrees from the fovea. The MS and cMS (12 central
locations) are projected to the average age of the sample (58 years old).
and healthy participants for either test (P = 0.055 for
microperimetry; P = 0.885 for FDT cMD, P = 0.894 for
FDT cMS). The slope was steeper for the FDT cMD (13.3
dB/log10(RGC count)) and FDT cMS (15.5 dB/log10(RGC
count)) than microperimetry MS (4.3 dB/log10(RGC count)).
However, this result needs to be interpreted in the context
of the different definitions of the dB scale used by the two
devices (see Discussion) and considering the small loss in
RGC count effectively observed for diabetic people in this
sample (see previous paragraph). A significant difference
in intercepts was found for the FDT cMS (P = 0.030) but
not for FDT cMD (P = 0.062) and microperimetry MS (P
= 0.339). The relationships with age-corrected microperi-
metric MS and FDT cMS are shown in Figure 3. There
was a significant correlation between the average cp-RNFL
and the global FDT MS (0.04 dB/μm, P = 0.028). The
relationship with the global MD, however, did not reach
significance, despite being very similar in magnitude (0.03
dB/μm, P = 0.074). All comparisons with MS were corrected
for age in the statistical model. The average cp-RNFL was
also compensated for ocular magnification45 and corrected
by AL.
Topographic Structure-Function Relationship. The
pointwise structure-function slopes for microperimetry
were shallow (Fig. 4), as expected in the partial summation
condition (see Appendix). The slopes were, however, all
statistically significant (P < 0.05) except at 1 degree of
eccentricity (P = 0.068). The only significant difference
in intercepts between healthy and diabetic patients was
found at 1 degree (P = 0.036). As expected, there was
no significant difference in slopes between healthy and
diabetic patients (P = 0.178).
The pointwise structure-function slopes for FDT sensitiv-
ity values (Fig. 5) were also shallow. The significance for
slopes and differences in intercepts between the two groups
is reported in Figure 5 for each location. A significant differ-
ence in intercepts was found for five locations. A signifi-
cant structure-function slope was found for nine locations.
As expected, there was no significant difference in slopes
between healthy and diabetic patients (P = 0.270).
DISCUSSION
We analyzed structural and functional data in a large number
of patients with DM (n = 134) with no signs of DR and
371 healthy controls. Our results support the hypothesis of
inner retinal loss prior to clinically evident vascular alter-
ations in diabetes. Critically, we could test this hypothesis
by excluding patients with DR, allowing us to isolate the
effect of early neuronal loss. Another strength of our study
is that the diagnosis of DM for many of the diabetic patients
was fairly recent (Table). This constitutes an optimal condi-
tion to study neuronal loss in its earliest phase, suggesting
that it might happen soon after or even before the clini-
cal diagnosis of DM. Another novel important aspect of our
analysis is that the results are framed in the context of an
accepted neural model for perimetric stimuli, which allowed
us to provide a mechanistic interpretation of the observed
structure-function relationship rather than simply report-
ing statistical associations between structural and functional
metrics. Such a model constitutes an accepted paradigm
for glaucoma but has not been previously tested for early
neuronal loss in diabetes.
Structural Metrics
The largest significant reduction in retinal thickness was
recorded for the GCL and IPL, with some mild, nonsignif-
icant changes to the outer retina. This is in agreement with
previous findings, showing thinning of the inner retina in
patients with no or mild DR.4,12–17 Despite some local vari-
ations, the neural loss appeared mostly diffuse. However,
most of the significant differences were found in sectors
where the layer of interest is normally thicker, indicating
a likely effect of a larger signal-to-noise ratio in areas where
measurements are more robust and have more room for vari-
ation. Such a result is in agreement with Van Dijk et al.,12,13,26
who reported significant changes only in the perifoveal
region. This can also explain the lack of observable differ-
ences in the RNFL, notoriously thin and difficult to measure
in the macular region. Indeed, when the normally thicker
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FIGURE 4. Scatterplot and regression lines for the topographic structure-function relationship for microperimetry. The regression lines have
the same slope for both healthy and diabetic patients. Local counts account for RGC displacement. The microperimetric sensitivity is projected
to the average age of the sample (58 years old).
cp-RNFL was analyzed, a significant, albeit small, loss was
identified in patients with DM. It is important to note that
retinal thinning is not the only structural change observed in
patients with DM and minimal DR. A comprehensive anal-
ysis by Gerendas et al.53 showed GCL-IPL thickening and
attributed it to initial diffuse swelling prior to the develop-
ment of evident macular oedema. However, these findings
pertained to patients with type 1 diabetes, including people
with mild DR. Instead, in our study, we carefully focused
our analysis on patients with no signs of DR to specifically
examine evidence of neural degeneration. Our DM cohort
only contained 19 patients with type 1 diabetes, too few to
be analyzed separately. However, despite not being signif-
icant, this group showed an average thinning of the GCL
compared to the healthy participants both in the raw (–0.47
μm) and age-corrected (–1.28 μm) estimates, in agreement
with the general trend for the DM cohort. Nevertheless, this
is an important aspect to consider when interpreting the
structure-function relationship (discussed later).
Functional Metrics
In agreement with previous results,18–20 PR-logCS was signif-
icantly reduced in diabetic patients (19% average age-
corrected reduction in CS). A significant reduction was also
observed in the BCVA, although the effect was smaller (12%
average age-corrected increase in minimum angle of reso-
lution). Such a small difference might explain why this
parameter failed to show significant differences in previous
reports.18,20
Importantly, we found a significant reduction in sensitiv-
ity with FDT perimetry in diabetic patients, confirming and
expanding previous findings. Previous studies were mainly
limited by the small sample size and the lack of a specific
analysis of the macular region.18,19,27–29 In our analysis, we
showed that the differences between healthy and diabetic
patients are larger for the central locations (cMD) than the
whole field (MD). This strengthens the evidence for neural
damage, since tests of the central visual field are usually
more reliable.54 We did not find any significant differences
between healthy and diabetic patients in the age-corrected
MS with microperimetry, despite a significant correlation
with the RGC count. This can be explained by a more careful
analysis of the structure-function relationship (see next para-
graph). Of note, the MAIA, differently from the Matrix FDT
perimeter, does not provide deviation values, hence the need
for statistical correction for age. However, the same age-
corrected model used for the central FDT MS still showed
a strongly significant difference between the two groups,
ruling out a lack of power in the statistical approach. Of
course, one limitation of our data set is the lack of either the
FDT or the microperimetry data for some of the participants.
This could have been avoided by only analyzing complete
data (76% of the overall sample, 88% of the diabetic cohort).
However, we decided to include all participants who had
performed at least one of the two perimetric tests to mini-
mize the risk of bias and to maximize the power of our
statistical analyses, conditioning our selection only on the
presence of the macular OCT scan.
Structure-Function Relationship
One core aspect of our analysis was the detailed study of
the structure-function relationship, especially in the macu-
lar region. This is important in order to interpret our find-
ings in the context of accepted neural models for peri-
metric responses. Unlike previous reports,18,20,26 we trans-
formed the measured GCL thickness into an estimate of RGC
counts, and this was a novel step. Such an approach allows a
more direct interpretation of the functional findings in light
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FIGURE 5. Scatterplot and regression lines for the topographic structure-function relationship for FDT. The regression lines have the same
slope for both healthy and diabetic patients. Local counts account for RGC displacement. *P < 0.05. **P < 0.01. Difference = difference in
intercepts between healthy and diabetic patients.
of the observed structural changes. Both FDT and MAIA
measurements showed a significant correlation with struc-
tural parameters in the global and topographical analyses.
For the global parameters, the slopes were steeper (greater
effect) for measurements from the FDT when compared to
those from MAIA. However, it is important to keep in mind
that the Matrix FDT equates one log10 step to 20 dB instead
of 10 dB. To transform the FDT values in the same scale
as microperimetry, it is sufficient to divide sensitivity and
slopes by 2. This calculation brings the structure-function
slope observed for the FDT cMS with the total central RGC
count to 7.75 dB/log10(RGC count), much closer to the value
observed for microperimetry (4.3 dB/log10(RGC count)), but
still steeper.
Despite both tests showing a significant correlation with
structural parameters, with global and local measurements,
only the FDT was able to show a significant difference
between diabetic and healthy participants. The lack of signif-
icant differences for microperimety can be explained by
considering pointwise sensitivities and the effect of spatial
summation on perimetric stimuli, and this is worthy of some
discussion here and in the Appendix. Indeed, the relation-
ship between the number of RGCs and perimetric sensitiv-
ity becomes very shallow if the number of stimulated RGCs
is larger than a critical amount (conventionally >101.5 for
SAP stimuli49), reducing the ability of the test to discriminate
early functional damage. This happens in the macular region
for G-III stimuli (used in microperimetry) because of the
high density of RGCs.49,50 Total summation conditions could
be obtained for the macula by changing the size or the dura-
tion of the stimuli49,55 and would be particularly valuable for
detecting the effect of early neural degeneration in diabetes.
In fact, undersampling due to RGC loss is expected to have a
greater effect on sensitivity for small test targets compared to
large test targets (see Appendix). However, FDT was able to
discriminate between the two groups regardless of this limi-
tation. Although such simple reasoning is more difficult to
apply to FDT stimuli, the even larger stimulus size is likely to
produce partial summation (see Appendix). One explanation
for this difference is that FDT might be able to detect early
cell dysfunction occurring in diabetic patients, in addition to
the changes explained by pure structural loss. This is concor-
dant with the finding that a significant difference in the inter-
cepts was detected in the structure-function relationship for
FDT metrics (with no significant differences in slope), effec-
tively highlighting a residual functional defect in diabetic
patients unexplained by structural changes. This residual
defect could be the consequence of concomitant changes in
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the functionality of the outer retina. However, given the lack
of significant thinning of the outer layers, this seems unlikely
for our data set. Of course, such a difference in intercepts
could also be explained by the limitations of the structural
OCT measurements. One key assumption in our structure-
function analyses is that changes in the measured thickness
values accurately represent the loss of neural tissue. This is
known not to be the case and is one of the reasons for the
floor effect in structural measurements, especially with more
advanced damage.47,56 For example, our quantification of
RGCs assumes that cellular density within a given volume of
tissue remains constant and the change in RGCs is accurately
reflected by the change in volume. Moreover, as previously
mentioned, inner retinal tissue thickening has also been
described53 in diabetic patients, likely due to subtle swelling
of the neural tissue. This would make our assumption of
constant density unreliable. However, it is unlikely for these
factors to have played a major role in our analyses, given
the absence of eyes with DR and the relatively early loss of
inner retinal tissue, far from the floor effect. Indeed, such
inaccuracies should have caused a significant difference in
intercepts between the two groups also for microperime-
try, which was not seen. This opens up potential applica-
tions of complex stimuli to more accurately investigate inner
retinal damage in diabetes. However, in other reports, tradi-
tional SAP was also shown to be effective in detecting reti-
nal dysfunction in diabetes18,28–31 and performed similarly
to FDT when compared directly.18 The recent introduction
of wide-field photopic white-on-white perimeters equipped
with fundus tracking technology57 might combine the accu-
racy of microperimetry with the benefit of traditional SAP.
The obvious advantage of circular stimuli is that, not having
to accommodate for patterns, they can be designed to be
arbitrarily localized (small), potentially increasing spatial
precision. However, as mentioned earlier, the characteristics
of the stimulus (duration/size) should ideally be optimized
to detect fine changes in the macular region (this point is
further expanded in the Appendix).
Effect of Disease Duration and HbA1C
We could not find any significant correlations of the struc-
tural or functional parameters with either the duration of the
disease or the percentage HbA1C in diabetic patients. The
measured impact of these factors on neuronal damage has
been variable across different reports.13,21,53,58 In our study
population, the average duration of the disease was short.
This was expected from our selection criteria, since patients
with type 2 diabetes and no DR are likely to have only been
recently diagnosed. This also means that the recorded dura-
tion is unlikely to accurately reflect the actual time course
of the disease. Longer durations were recorded for patients
with type 1 diabetes, a small fraction of our sample.
A similar consideration can be made for the HbA1C, since
the value measured in our cohort is representative of the
metabolic control under treatment, with little connection to
the metabolic imbalance that would have determined the
initial neural damage. One limitation of this analysis was
the fact that the HbA1C was not available for all participants
(88% of diabetic patients and 73% of healthy participants).
This constitutes a limitation also for the exclusion of type 2
DM in the healthy cohort. However, only 37 of the healthy
participants (10% of the overall healthy cohort) for whom
HbA1C was not measured were older than 40 years of age
and therefore at reasonable risk of having undetected type
2 DM. Thus, such a misclassification might have reduced the
observed differences between the two cohorts in our data
set but is unlikely to have produced a large effect.
CONCLUSIONS
Our data provide structural and functional evidence to
support the hypothesis of neuronal damage in DM, prior
to clinically evident vascular changes, in a large cohort of
diabetic patients and healthy controls. However, most of
these modifications are subtle and difficult to detect. The
macular region has the potential to be the optimal “ground”
to integrate structural and functional information for early
detection of neural degeneration. Although these changes
are too small to directly impact on patients’ vision, their
detection is clinically meaningful, as it could help predict
the insurgence of clinically evident vascular alterations.5
However, functional tests should be optimized to better
probe the central visual field, taking the effect of neural
summation into account, for example. Future investigations
with better designed functional tests are needed to assess
the clinical effectiveness of structure-function integration
to detect early neural damage in diabetes. Our data also
confirm that a simple measurement of BCVA might be insuf-
ficient to fully characterize the changes in visual function
observed in diabetes and that perimetric tests should be
considered by researchers investigating diabetic neuronal
damage. It is also important to highlight that clinical studies
such as this cannot entirely rule out the presence of preex-
isting microalterations of the retinal vasculature as a primary
source of neuronal damage, since only clinically evident
vascular alterations can be excluded in patients. Further
structure-function analyses including parameters from OCT-
angiography scans might help shed light into this aspect and
will be the subject of future work.
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APPENDIX
Flowchart of the Selection Steps
The flowchart in Figure A1 reports the selection
steps applied to the initial samples. The criteria
for patients to be invited for the NISA study were
based on the information collected at the time of the
NICOLA study. For example, people with early AMD
during the NICOLA study might have converted
to intermediate/advanced AMD and therefore later
excluded from this analysis. No such prior informa-
tion was available for the diabetic cohort from the
Belfast Trust Diabetic Retinopathy Hospital Clinics
at QUB.
Spatial Summation of Perimetric Stimuli
Spatial summation describes how sensory systems
combine input from multiple channels to produce
the final psychophysical sensation (in this case,
perimetric sensitivity). For simple circular perimet-
ric stimuli, such as in the case of the MAIA, the
number of channels is often equated to the number
of RGCs being stimulated.49,59 This number can
change because of the size of the stimulus or
the local density of RGCs.49,55,59 In SAP, the rela-
tionship between the log10(RGC count) and sensi-
tivity in dB has a slope of 10 up to a certain
RGC count (total or complete summation), after
which the slope becomes much shallower, usually
2.5 (partial summation). In traditional SAP with
photopic background illumination (10 cd/m2) and
200-ms round stimuli, the break point is conven-
tionally located at 101.5 RGCs.49 Although using
a mesopic background (1.27 cd/m2), such as in
the MAIA, could change the location of the break-
point,60,61 large differences are not expected for
changes of less than 1 log10 unit in background
illumination, as in this case. In fact, the theoret-
ical framework is confirmed by our experimental
data. Figure A2, left panel, shows the relationship
between the log10(RGC count) and microperimet-
ric sensitivity. The empirical slope fitted using the
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FIGURE A1. Flowchart of the selection steps detailed in the methods.
FIGURE A2. Observed structure-function relationship compared to the theoretical framework of spatial summation. The observed relationship
for the FDT is plotted as two separate lines to reflect the significant difference in intercepts between the diabetic and healthy participants.
Sensitivity is projected to the average age of the sample (58 years old).
overall data set yielded a value of 2.29 (95% CI,
2.22–2.37) dB/log10(RGC count), remarkably close
to the theoretical prediction. Indeed, even for the
most peripheral locations, the number of stimulated
ganglion cells was mostly beyond the critical 101.5.
Of note, the empirical slope was fitted using a linear
mixed model with random intercepts to account for
correlated measures from the same eye and with
age as a covariate to account for the aging effect
beyond the normal loss of RGCs. In this frame-
work, significant differences in intercepts between
the diabetic patients and healthy controls would
indicate a sensitivity loss unexplained by the struc-
tural loss, for example, in the case of dysfunction.
This was not observed for microperimetric stimuli.
Such a theoretical framework can be applied
for FDT stimuli, although it is harder to inter-
pret due to their complex features.41 Nevertheless,
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FIGURE A3. Example of how the microperimetric test could be modified to improve detection of neural damage. (A) Differences between
perimetric responses from a healthy and degraded RGC mosaic are amplified by smaller stimuli that operate in total summation conditions.
The gray lines connect the number of RGCs stimulated in each condition with the predicted sensitivity. Their difference can be read on
the vertical axis. (B) This principle might have provided different results for microperimetry in this study; the black line represents the
estimated average difference in sensitivity with different stimulus sizes, according to the model; the blue shaded area encloses the 95%
confidence intervals for the difference, estimated from a linear mixed model. The vertical lines indicate the size of typical Goldmann stimuli.
The estimated difference was significant with a Goldmann I stimulus (P values reported at the top).
the much larger stimulus size is likely to produce
partial summation conditions. Indeed, the observed
slope was 2.29 (95% CI, 1.97–2.62) dB/log10(RGC
count). This is, however, much shallower than
microperimetry, considering that for the Matrix
FDT, one log10 step corresponds to 20 dB instead of
10 dB, leading to slope estimates that are doubled
in value. In this case, as for the main analysis, there
was a significant difference in the intercept between
the two groups (P= 0.0105), and this is represented
in Figure A2, right panel.
Figure A3 shows how different results could be
obtained by performing the microperimetric test in
total summation conditions, for example, by reduc-
ing the stimulus size. For this calculation, we scaled
the log10(RGC count) estimated for Goldmann III
stimuli to other stimulus sizes. We then calcu-
lated the expected sensitivity for the corresponding
number of stimulated RGCs according to the model
and added the residuals calculated from the real
data. The estimated average difference between the
two groups (and its standard error) was then calcu-
lated by combining the values at different locations
using a linear mixed model. As expected, the differ-
ence became larger for smaller stimulus sizes (Fig.
A3B) and reached significance with a Goldmann
I. This calculation does not account for possible
changes in the variability of the perimetric response
that could be introduced when testing with smaller
stimulus sizes. However, this is not an intrinsic limi-
tation of the test, since strategies can be devised
to maintain constant variability at different sensi-
tivities.62 Moreover, the breakpoint location might
change based on adaptation conditions and back-
ground luminance,60,61 but a Goldmann I stimulus
is expected to be within the range of total summa-
tion in the macula even for mesopic testing condi-
tions.63
